|
AU2010223919B2
(en)
|
2009-03-13 |
2016-03-31 |
Les Laboratoires Servier |
Methods and compositions for cell-proliferation-related disorders
|
|
WO2010118063A2
(en)
|
2009-04-06 |
2010-10-14 |
Agios Pharmaceuticals, Inc. |
Therapeutic compositions and related methods of use
|
|
ES2618630T3
(es)
|
2009-06-29 |
2017-06-21 |
Agios Pharmaceuticals, Inc. |
Composiciones terapéuticas y métodos de uso relacionados
|
|
RU2561132C2
(ru)
|
2009-06-29 |
2015-08-20 |
Аджиос Фармасьютикалз, Инк. |
Производные хинолинсульфонамидов и их применение для модулирования пкм2 активности
|
|
WO2011050211A2
(en)
|
2009-10-21 |
2011-04-28 |
Agios Pharmaceuticals, Inc. |
Methods and compositions for cell-proliferation-related disorders
|
|
EP3561077B1
(en)
|
2009-10-21 |
2022-12-21 |
Les Laboratoires Servier |
Methods for cell-proliferation-related disorders
|
|
CA2821975A1
(en)
|
2010-12-17 |
2012-06-21 |
Shunqi Yan |
N-(4-(azetidine-1-carbonyl)phenyl)-(hetero-) arylsulfonamide derivatives as pyruvate kinase m2 pkm2 modulators
|
|
WO2012088314A1
(en)
|
2010-12-21 |
2012-06-28 |
Agios Pharmaceuticals, Inc. |
Bicyclic pkm2 activators
|
|
TWI549947B
(zh)
|
2010-12-29 |
2016-09-21 |
阿吉歐斯製藥公司 |
治療化合物及組成物
|
|
SG194697A1
(en)
|
2011-05-03 |
2013-12-30 |
Agios Pharmaceuticals Inc |
Pyruvate kinase activators for use in therapy
|
|
CN102827170A
(zh)
|
2011-06-17 |
2012-12-19 |
安吉奥斯医药品有限公司 |
治疗活性组合物和它们的使用方法
|
|
CN102827073A
(zh)
*
|
2011-06-17 |
2012-12-19 |
安吉奥斯医药品有限公司 |
治疗活性组合物和它们的使用方法
|
|
KR20140069235A
(ko)
*
|
2011-09-27 |
2014-06-09 |
노파르티스 아게 |
돌연변이체 idh의 억제제로서의 3-피리미딘-4-일-옥사졸리딘-2-온
|
|
NZ627096A
(en)
|
2012-01-06 |
2017-02-24 |
Agios Pharmaceuticals Inc |
Triazinyl compounds and their methods of use
|
|
US9474779B2
(en)
*
|
2012-01-19 |
2016-10-25 |
Agios Pharmaceuticals, Inc. |
Therapeutically active compositions and their methods of use
|
|
UY34632A
(es)
|
2012-02-24 |
2013-05-31 |
Novartis Ag |
Compuestos de oxazolidin- 2- ona y usos de los mismos
|
|
WO2014062511A1
(en)
|
2012-10-15 |
2014-04-24 |
Agios Pharmaceuticals, Inc. |
Therapeutic compounds and compositions
|
|
US9296733B2
(en)
|
2012-11-12 |
2016-03-29 |
Novartis Ag |
Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases
|
|
EP2970240B1
(en)
|
2013-03-14 |
2018-01-10 |
Novartis AG |
3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
|
|
WO2014197835A2
(en)
|
2013-06-06 |
2014-12-11 |
The General Hospital Corporation |
Methods and compositions for the treatment of cancer
|
|
CN105593215B
(zh)
|
2013-07-11 |
2019-01-15 |
安吉奥斯医药品有限公司 |
用于治疗癌症的作为idh2突变体抑制剂的2,4-或4,6-二氨基嘧啶化合物
|
|
WO2015003355A2
(en)
*
|
2013-07-11 |
2015-01-15 |
Agios Pharmaceuticals, Inc. |
Therapeutically active compounds and their methods of use
|
|
MY185687A
(en)
|
2013-07-11 |
2021-05-30 |
Agios Pharmaceuticals Inc |
N,6-bis(aryl or heteroaryl)-1,3,5-triazine-2,4-diamine compounds as idh2 mutants inhibitors for the treatment of cancer
|
|
WO2015003360A2
(en)
*
|
2013-07-11 |
2015-01-15 |
Agios Pharmaceuticals, Inc. |
Therapeutically active compounds and their methods of use
|
|
US9579324B2
(en)
|
2013-07-11 |
2017-02-28 |
Agios Pharmaceuticals, Inc |
Therapeutically active compounds and their methods of use
|
|
US20150031627A1
(en)
|
2013-07-25 |
2015-01-29 |
Agios Pharmaceuticals, Inc |
Therapeutically active compounds and their methods of use
|
|
MX368464B
(es)
*
|
2013-12-05 |
2019-10-02 |
Pfizer |
Acrilamidas de pirrolo[2,3-d]pirimidinilo, pirrolo[2,3-b]pirazinil o y pirrolo[2,3-d]piridinilo.
|
|
AU2015217788B2
(en)
|
2014-02-11 |
2019-06-27 |
Deutsches Krebsforschungszentrum, Stiftung Des Öffentlichen Rechts |
Benzimidazol-2-amines as mIDH1 inhibitors
|
|
CN105980365B
(zh)
|
2014-02-11 |
2019-06-21 |
拜耳医药股份公司 |
作为mIDH1抑制剂的苯并咪唑-2-胺
|
|
KR20240010105A
(ko)
|
2014-03-14 |
2024-01-23 |
아지오스 파마슈티컬스 아이엔씨. |
치료적으로 활성인 화합물의 약제학적 조성물
|
|
CN106170480B
(zh)
*
|
2014-05-09 |
2019-09-20 |
上海科胜药物研发有限公司 |
新的沃替西汀中间体及其合成方法
|
|
CA2961811C
(en)
|
2014-09-19 |
2021-11-02 |
Forma Therapeutics, Inc. |
Pyridinyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
|
|
WO2016044789A1
(en)
|
2014-09-19 |
2016-03-24 |
Forma Therapeutics, Inc. |
Pyridin-2(1h)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
|
|
ES2768694T3
(es)
|
2014-09-19 |
2020-06-23 |
Forma Therapeutics Inc |
Composiciones de quinolinona pirimidinas como inhibidores de isocitrato dehidrogenasa mutante
|
|
CA2961807A1
(en)
*
|
2014-09-19 |
2016-03-24 |
Forma Therapeutics, Inc. |
Phenyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
|
|
ES2905564T3
(es)
|
2014-12-22 |
2022-04-11 |
Us Health |
Inhibidores mutantes de IDH1 útiles para tratar el cáncer
|
|
US10294206B2
(en)
|
2015-04-21 |
2019-05-21 |
Forma Tm2, Inc. |
Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
|
|
US10407419B2
(en)
|
2015-04-21 |
2019-09-10 |
Forma Therapeutics, Inc. |
Quinolinone five-membered heterocyclic compounds as mutant-isocitrate dehydrogenase inhibitors
|
|
FI3307271T3
(fi)
|
2015-06-11 |
2023-10-17 |
Agios Pharmaceuticals Inc |
Pyruvaattikinaasin aktivaattorien käyttämisen menetelmä
|
|
EP3340978A4
(en)
|
2015-08-24 |
2019-04-10 |
The Methodist Hospital |
COMPOSITIONS AND METHODS FOR TREATING THE RECOGNITION AND TREATMENT OF TUMORS OF THE EWING FAMILY
|
|
PT3362066T
(pt)
|
2015-10-15 |
2021-11-16 |
Celgene Corp |
Terapia de combinação para tratar malignidades
|
|
SG11201803088PA
(en)
|
2015-10-15 |
2018-05-30 |
Agios Pharmaceuticals Inc |
Combination therapy for treating malignancies
|
|
EP3397625A4
(en)
*
|
2015-12-30 |
2019-12-25 |
Agios Pharmaceuticals, Inc. |
TREATMENT OF TUMORS WITH MUTANT ISOCITRATE DEHYDROGENASE
|
|
WO2017153952A1
(en)
*
|
2016-03-10 |
2017-09-14 |
Glaxosmithkline Intellectual Property Development Limited |
5-sulfamoyl-2-hydroxybenzamide derivatives
|
|
WO2017162156A1
(zh)
*
|
2016-03-22 |
2017-09-28 |
正大天晴药业集团股份有限公司 |
丙啶磺酰胺类化合物及其使用方法
|
|
MA48459B1
(fr)
*
|
2017-04-24 |
2021-09-30 |
Aurigene Discovery Tech Ltd |
Méthodes d'utilisation de dérivés de benzotriazole trisubstitués en tant qu'inhibiteurs de dihydroorotate oxygénase
|
|
US20180369206A1
(en)
|
2017-04-24 |
2018-12-27 |
Aurigene Discovery Technologies Limited |
Methods of Use for Trisubstituted Benzotriazole Derivatives as Dihydroorotate Oxygenase Inhibitors
|
|
CN109897044A
(zh)
*
|
2017-12-07 |
2019-06-18 |
北京大学 |
抗神经病理性疼痛化合物及其制备方法
|
|
KR102861339B1
(ko)
|
2018-02-20 |
2025-09-19 |
르 라보레또레 쎄르비에르 |
삼치환 벤조트리아졸 유도체의 사용 방법
|
|
US11013734B2
(en)
|
2018-05-16 |
2021-05-25 |
Forma Therapeutics, Inc. |
Treating patients harboring an isocitrate dehydrogenase-1 (IDH-1) mutation
|
|
US11311527B2
(en)
|
2018-05-16 |
2022-04-26 |
Forma Therapeutics, Inc. |
Inhibiting mutant isocitrate dehydrogenase 1 (mIDH-1)
|
|
US10532047B2
(en)
|
2018-05-16 |
2020-01-14 |
Forma Therapeutics, Inc. |
Solid forms of ((S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile
|
|
US11013733B2
(en)
|
2018-05-16 |
2021-05-25 |
Forma Therapeutics, Inc. |
Inhibiting mutant isocitrate dehydrogenase 1 (mlDH-1)
|
|
WO2019222553A1
(en)
|
2018-05-16 |
2019-11-21 |
Forma Therapeutics, Inc. |
Inhibiting mutant idh-1
|
|
CN108822082B
(zh)
*
|
2018-06-06 |
2020-11-03 |
青岛科技大学 |
一种含氟吡啶哌嗪酰胺类化合物及其应用
|
|
US10980788B2
(en)
|
2018-06-08 |
2021-04-20 |
Agios Pharmaceuticals, Inc. |
Therapy for treating malignancies
|
|
CN116768806B
(zh)
*
|
2022-03-11 |
2026-01-02 |
中国农业大学 |
取代的1,2,3-三唑类化合物及其制备方法和在防治植物病害中的用途
|
|
CN114685399A
(zh)
*
|
2022-04-26 |
2022-07-01 |
河北广祥制药有限公司 |
一种乌拉地尔中间体1-(2-甲氧基苯基)哌嗪及其盐的制备方法
|
|
CN116425653A
(zh)
*
|
2023-03-22 |
2023-07-14 |
烟台盛凯伦化学科技有限公司 |
一种n,n’-二(对乙氧基苯基)-1,4-苯二甲亚胺的制备方法
|
|
CN121548417A
(zh)
*
|
2023-05-18 |
2026-02-17 |
康卡洛治疗公司 |
P27的小分子抑制剂
|